Since our discovery of Epithelial- and Mesenchymal Stem Cells in the mammalian umbilical cord lining, we have developed unique techniques for processing these stem cells for optimal potency. Our patents cover “mammalian umbilical cord lining”, and we work on both human and animal derived stem cells.
Through our subsidiaries, CordLabs Pte Ltd and CordLabs Asia Pte Ltd, we are licensing our proprietary technology for harvesting and storing of umbilical cord lining tissue to our cord blood bank partners. Only our licensed partners are able to provide parents who wish to store their baby’s cord lining tissue with the assurance that their tissue can be used for therapies when needed. All cord lining tissue banked with our partners will be included in the Global Cord Registry, and only tissue registered therein will be legally available for therapies.
What are Cord Lining Stem Cells?
The cord lining is the outermost layer of the umbilical cord that forms the connection between a baby and its mother. After a child is born, the umbilical cord is typically discarded as medical waste. However, scientists have discovered that the umbilical cord is in fact very rich in stem cells. The cord blood contains hematopoietic stem cells as well as mesenchymal stem cells. The cord tissue itself contains mesenchymal stem cells as well as epithelial stem cells.
Our scientists discovered that the lining of the umbilical cord is the part of the cord tissue which is the richest source of Epithelial and Mesenchymal stem cells.
The umbilical cord has a proven track record as a rich source of progenitor stem cells both from the blood vessel endothelium as well as from the contained cord blood, which is already being banked in numerous centres around the world as a source of autologous haematopoietic stem cells for future use. The addition of Epithelial and Mesenchymal stem cells from its amniotic membrane strengthens its versatility.
What really differentiates this stem cell source from other sources (for example bone marrow or adipose (fat) tissue) is the total lack of morbidity both to mother and infant. This cell derivation can be thought of coming from a source which is disposable- which is exactly what happens to the placenta and umbilical cord post-delivery!
Patent Applications have been successful in numerous territories for processes of stem cell derivation as well as therapeutic uses.
The epithelial cells derived have typical polyhedral morphology and the mesenchymal cells are characteristically spindle-shaped: both have a plump undifferentiated appearance.